Breast Cancer Clinical Trial
A Study of PF-07260437 in Advanced or Metastatic Solid Tumors
Summary
A study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of PF-07260437, a B7-H4 x CD3 bispecific mAb, in participants aged ≥18 years of age with advanced or metastatic breast cancer, ovarian cancer or endometrial cancer. Adult participants with other advanced or metastatic high B7-H4 expressing tumors may be considered after discussion with and approval from sponsor.
Eligibility Criteria
Inclusion Criteria:
Part 1: Histological/cytological diagnosis of selected locally advanced or metastatic breast cancer, endometrial cancer and ovarian cancer
Part 2A:In second line or more, participants with histological/cytological diagnosis of locally advanced or metastatic HR+ HER2- breast cancer showing high B7-H4 expression
Part 2B: In second line or more participants with histological or cytological diagnosis of locally advance or metastatic HR+ Her2- breast cancer or triple negative breast cancer (TNBC) with no biomarker pre-selection
Part 2C: In second line or more participants with histological diagnosis of locally advance or metastatic triple negative breast cancer with high B7-H4 expression
Thyroid function within normal laboratory range; in participants with abnormal thyroid function if Free T4 is normal and participant is clinically euthyroid, participants is eligible
Exclusion Criteria:
Participants with any active malignancy within 3 years prior to enrollment
Participants with advanced/metastatic, symptomatic, visceral spread, that are at risk of life-threatening complications in the short term (including participants with massive uncontrolled effusions [pleural, pericardial, peritoneal], pulmonary lymphangitis, and over 50% liver involvement).
History of Grade ≥3 immune mediated adverse events (including liver function tests that where considered drug related and cytokine release syndrome) that was considered related to prior immune modulatory therapy (eg, immune checkpoint inhibitors, co stimulatory agents, etc.) and required immunosuppressive therapy within 1 year of treatment.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 12 Locations for this study
Duarte California, 91010, United States
Tampa Florida, 33612, United States
Tampa Florida, 33612, United States
Chicago Illinois, 60637, United States
New Lenox Illinois, 60451, United States
Orland Park Illinois, 60462, United States
Bronx New York, 10461, United States
San Antonio Texas, 78229, United States
Edmonds Washington, 98026, United States
Seattle Washington, 98104, United States
Seattle Washington, 98109, United States
Seattle Washington, 98195, United States
Rio Piedras , 00935, Puerto Rico
Rio Piedras , 00935, Puerto Rico
How clear is this clinincal trial information?